Edition:
United States

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

337.42USD
18 Jan 2019
Change (% chg)

$-0.92 (-0.27%)
Prev Close
$338.34
Open
$340.33
Day's High
$340.50
Day's Low
$334.94
Volume
622,852
Avg. Vol
529,978
52-wk High
$388.67
52-wk Low
$249.24

Chart for

About

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis... (more)

Overall

Beta: 0.91
Market Cap(Mil.): $65,242.08
Shares Outstanding(Mil.): 201.48
Dividend: --
Yield (%): --

Financials

  BIIB.OQ Industry Sector
P/E (TTM): 15.41 29.45 30.88
EPS (TTM): 21.02 -- --
ROI: 21.62 14.34 13.80
ROE: 32.75 15.85 15.29

Fed Circuit declines to reconsider order upholding Biogen MS drug patents

A federal appeals court on Wednesday said it would not reconsider its recent decision affirming the validity of Biogen Inc’s key patent on its blockbuster multiple sclerosis drug Tecfidera.

Jan 02 2019

Ireland demands $1.9 billion in back taxes from Perrigo

DUBLIN Ireland's tax authorities have demanded that drugmaker Perrigo , formerly known as Elan, pay 1.64 billion euros ($1.9 billion) in taxes relating to the calendar year 2013, a U.S. securities filing showed.

Dec 21 2018

Ireland demands $1.9 bln in back taxes from Perrigo

DUBLIN, Dec 21 Ireland's tax authorities have demanded that drugmaker Perrigo, formerly known as Elan, pay 1.64 billion euros ($1.9 billion) in taxes relating to the calendar year 2013, a U.S. securities filing showed.

Dec 21 2018

Swiss stocks - Factors to watch on Dec. 21

ZURICH/BERLIN, Dec 21 The Swiss blue-chip SMI, which is down 10.3 percent on the year, was seen opening 0.1 percent lower at 8,404 points on Friday, according to premarket indications by bank Julius Baer.

Dec 21 2018

U.S. body says gene therapy may be more cost effective for spinal muscular atrophy

NEW YORK/ZURICH Biogen Inc's Spinraza treatment for spinal muscular atrophy and Swiss drugmaker Novartis AG's experimental gene therapy are both expensive, but the gene therapy could be more cost effective once more is known about its U.S. price and long-term success rates, a preliminary report from an independent U.S. nonprofit organization said on Thursday.

Dec 20 2018

UPDATE 1-U.S body says gene therapy may be more cost effective for spinal muscular atrophy

NEW YORK/ZURICH, Dec 20 Biogen Inc's Spinraza treatment for spinal muscular atrophy and Swiss drugmaker Novartis AG's experimental gene therapy are both expensive, but the gene therapy could be more cost effective once more is known about its U.S. price and long-term success rates, a preliminary report from an independent U.S. nonprofit organization said on Thursday.

Dec 20 2018

U.S body says gene therapy may be more cost effective for spinal muscular atrophy

NEW YORK/ZURICH, Dec 20 Biogen Inc's Spinraza treatment for spinal muscular atrophy and Swiss drugmaker Novartis AG's experimental gene therapy are both expensive, but the gene therapy could be more cost effective once more is known about its U.S. price and long-term success rates, a preliminary report from an independent U.S. nonprofit organization said on Thursday.

Dec 20 2018

Novartis's pricing might be tested with costly eye therapy

ZURICH Novartis's price-setting muscle is about to be tested after it won European Union approval for a blindness-fighting gene therapy whose $850,000 list cost in the United States has been labeled too expensive by some groups.

Nov 23 2018

UPDATE 1-Novartis's pricing might be tested with costly eye therapy

* Swiss drugs group forging into pricey rare-disease meds (Adds comments, context about pricing, analyst quote)

Nov 23 2018

Eisai, Biogen Alzheimer's data fails to convince skeptics

Eisai Co Ltd and partner Biogen Inc said on Thursday that the highest dose of their experimental Alzheimer's disease drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data and Biogen shares fell about 2 percent.

Oct 25 2018

Earnings vs. Estimates